Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $44.1 million.

  • Ani Pharmaceuticals' Cash from Operations rose 25317.46% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.7 million, marking a year-over-year increase of 8377.13%. This contributed to the annual value of $64.0 million for FY2024, which is 4618.57% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Cash from Operations of $44.1 million as of Q3 2025, which was up 25317.46% from $75.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Cash from Operations ranged from a high of $75.8 million in Q2 2025 and a low of -$18.9 million during Q1 2022
  • In the last 5 years, Ani Pharmaceuticals' Cash from Operations had a median value of $17.4 million in 2024 and averaged $16.3 million.
  • In the last 5 years, Ani Pharmaceuticals' Cash from Operations crashed by 486514.52% in 2022 and then surged by 111681.82% in 2023.
  • Ani Pharmaceuticals' Cash from Operations (Quarter) stood at -$12.2 million in 2021, then surged by 63.89% to -$4.4 million in 2022, then soared by 1116.82% to $44.7 million in 2023, then plummeted by 64.55% to $15.9 million in 2024, then skyrocketed by 177.77% to $44.1 million in 2025.
  • Its Cash from Operations stands at $44.1 million for Q3 2025, versus $75.8 million for Q2 2025 and $35.0 million for Q1 2025.